Automatic Immunoassay Analyzer market is anticipated to grow at a CAGR of 14.8% during the forecast period (2023-2030). Automatic Immunoassay analyzers are the type of medical devices that are used for the immunoassay test which helps in the detection of protein analyze present in a specific blood sample. Their usage is growing owing to their benefits in publishing tests and the accurateness of their operations. The rise in demand for immunoassay to diagnose and detect microorganism-based infections is amongst the significant factors expected to fuel the growth and demand of immunoassay analyzers market.

SOURCE: U.S. Department of Health & Human Services

Segmental Outlook 

The global Automatic Immunoassay Analyzer market is segmented on the Application and product. Based on the application, the market is sub-segmented into infectious diseases, endocrinology, drug monitoring, chronic diseases, and allergy testing. based on the product, the market is sub-segmented into immunofluorescence, chemiluminescence, enzyme linked fluorescent system, and radioimmunoassay. Among the application, the Chronic Diseases sub-segment is anticipated to hold a considerable share of the market, owing to the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, cancer, and infectious diseases has driven the demand for diagnostic tools like immunoassay analyzers.

The Infectious diseases Sub-Segment is Anticipated to Hold a Considerable Share of the Global Automatic Immunoassay Analyzer Market

Among the application, the infectious diseases sub-segment is expected to hold a considerable share of the global automatic immunoassay analyzer market. The segmental growth is attributed to Increasing prevalence of infectious diseases is one of the crucial factors that is conventional to drive automated immunoassay analyzers market growth. Early detection of infectious diseases is important to reduce the possibility of severe damage to the body. Thus, proper and accurate screening of infections such as Hepatitis, influenza, STDs, and numerous other infections in minimal time is projected to be a major market growth factor. Hence companies are focusing on introducing new and advanced automatic solution for better screening. For an instance, in July 2023, Beckman Coulter Diagnostics, received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry. Designed for small-to-medium-sized laboratories, the DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to optimize laboratory workflows and support critical clinical decisions.

Regional Outlook

The global automatic immunoassay analyzer market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing the rapid technological developments and increase in usage of immunoassay testing for various applications. For instance, in April 2023, Chinese firm Fapon Biotech Inc. announced its innovative chemiluminescence one-stop solution strategy. Fapon chemiluminescence one-stop solution is designed to provide a complete range of chemiluminescence products and services, consisting of different levels of fully automatic chemiluminescence analysers with open system platforms, reagent development support, as well as high quality core raw material in bulk production. Fapon Biotech aims to help local in-vitro diagnostic (IVD) partners quickly extend their product portfolio and streamline their production processes, as well as accelerate their business in the chemiluminescence immunoassay industry.

Global Automatic Immunoassay Analyzer Market Growth by Region 2023-2030

The North America Region is Expected to Grow at a Significant CAGR in the Global Automatic Immunoassay Analyzer Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising in Geriatric Population and Rapid Change in Lifestyle. Correspondingly owing to easy availability of medical products along with advanced technologies and the high adoption rate of the automatic products in healthcare. For an instance, in January 2023, Qiagen has launched the EZ2 Connect MDx IVD platform for automated sampling in diagnostic laboratories. The company is offering the platform for widescale use 18 months after it was made available for research. The EZ2 Connect MDx device has a high degree of automation and enables laboratories to perform parallel purification of DNA and RNA from up to 24 samples in 30 minutes. Available in Canada, the US and other countries, the platform has EU CE-IVD compliance marking for in-vitro devices (IVD) for the European Union and other countries accepting this designation.

Hence, there is considerable shift of the country towards the adoption of the Automatic Immunoassay Analyzer production. Owing to changing trends and advancements in Medical Devices are other key factors expected to continue to support market revenue growth in the region. For an instance, in July 2023, Beckman Coulter, revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer, addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The DxI 9000 Analyzer has shown capability to develop increasingly sensitive and clinically relevant assays enabling the platform to keep pace with tomorrow's testing requirements as healthcare providers and pharmaceutical companies take aim at evermore challenging diseases. 

Market Players Outlook

The major companies serving the global automatic immunoassay analyzer market include F. Hoffmann-La Roche Ltd., Abbott, BD, Beckman Coulter, Inc., Ortho Clinical Diagnostics, bioMérieux SA, Biokit S.A, The Binding Site Group Ltd., Quidel Corporation, Immunodiagnostic Systems, Merck KGaA, Olympus Corporation, Nova Century Scientific, Inc., Luminex Corporation, DiaSorin S.p.A., Bio-Rad Laboratories, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2023, Agilent Technologies Inc. announced their xCELLigence RTCA HT (real-time cell analysis high-throughput) platform which integrates with the BioTek BioSpa 8 Automated Incubator. Developed in response to market needs, this combination enables a higher level of workflow automation that provides novel functionality for the development of label-free high-throughput potency assays for the immuno-oncology space and high-throughput viral cytopathic effects (CPE) assays for the vaccine market.

The Report Covers

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global automatic immunoassay analyzer market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.